Skip to main content

Table 3 Model input parameters and their uncertainty distributions

From: Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study

Parameter

   Value

Mean (SE or 95%CI)

Uncertainty distribution

Sources and assumptions

RR of IHD with treatment

   

-Statin

-Diuretic

-Calcium channel blocker

-ACE inhibitor

-Beta-blocker

0.70 (0.61 to 0.81)

0.86 (0.75 to 0.98)

0.85 (0.78 to 0.92)

0.83 (0.78 to 0.89)

0.78 (0.89 to 1.02)

Normal (lnRR)

Meta-analyses of primary prevention trials [5, 6, 47]

RR of stroke with treatment

   

-Statin

-Diuretic

-Calcium channel blocker

-ACE inhibitor

-Beta-blocker

0.81 (0.71 to 0.93)

0.62 (0.53 to 0.72)

0.66 (0.58 to 0.75)

0.78 (0.66 to 0.92)

0.70 (0.83 to 0.99)

Normal (lnRR)

Meta-analyses of primary prevention trials [5, 6, 47]

RR of stroke in IHD

   

-Men

-Women

1.32 (0.20)

1.88 (0.30)

Normal (lnRR)

Busselton study [48, 49]

RR of IHD in stroke

   

-Men

-Women

2.64 (0.07)

2.85 (0.04)

Normal (lnRR)

Busselton study [48, 49]

IHD treatment cost

   

-First year

-Subsequent years

$12,921

$4,539

Uniform

Lim [43]. Uniform distribution assumed to vary by ±25% around mean.

Stroke treatment cost

   

-First year

-Subsequent years

$23,581

$3,201

Uniform

Lim [43]. Uniform distribution assumed to vary by ±25% around mean.

Proportion of population visiting a GP in one year

   

35–44 yrs

45–54 yrs

55–64 yrs

65–74 yrs

75+ yrs

Men Women

73% 88%

81% 89%

81% 89%

93% 94%

99% 99%

–

BEACH data [17]

Proportion of GPs measuring absolute risk

65% (6.5%)

Beta

Practice Incentives Program data [50].

First year drug discontinuation rate

40% (8%)

Beta

Estimate from Australian survey data [21, 22]. Standard error assumed to be 20% of point estimate.

  1. NB. All costs adjusted to 2008 Australian dollars using Australian health price deflators [39]. RR – relative risk.